Abstract
N-Alkyl-2-(substitutedbenzamido) benzamides and methyl 2-(2-(substitutedbenzamido) benzamido) alkanoates were prepared by either the reaction of amines or amino acid esters with benzoxazine derivatives or the DCC coupling of 2-substitutedbenzamido benzoic acid with amines or amino acid esters. Methyl 2-(2-(4-chlorobenzamido)benzamido alkanoates were used as the key intermediate for the preparation of dipeptide-coupled benzamides via azide and DCC coupling methods. The investigated compounds were subjected to in silico molecular docking as agonist for human σ1 receptor through their binding energies and analysis of ligand–receptor interactions and prediction study to their physicochemical properties and drug-likeness scores. Moreover, compounds with the highest binding affinity toward the target were screened against breast MCF-7 and liver A549 cancer cell lines to test their cytotoxic activities. Compounds 11a, 3a, 8c, 12a and 13b showed potent cytotoxic activity for the tested compounds against MCF-7 cell line with low IC50 values, especially for 11a (5.3 µM compared to the standard drug 5-FU 5.8 µM). Based on the identification of this hit candidate, new potent σ1 receptor with anti-cancer activity could be designed.
Similar content being viewed by others
References
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, CA Cancer J. Clin. 68, 394 (2018)
S. BW, W. CP, World Cancer Report 2014 (2014)
R. Moreno-Sánchez, A. Marín-Hernández, E. Saavedra, J.P. Pardo, S.J. Ralph, S. Rodríguez-Enríquez, Int. J. Biochem. Cell Biol. 50, 10 (2014)
S.B. Hellewell, A. Bruce, G. Feinstein, J. Orringer, W. Williams, W.D. Bowen, Eur. J. Pharmacol. 268, 9 (1994)
R. Quirion, W.D. Bowen, Y. Itzhak, J.L. Junien, J.M. Musacchio, R.B. Rothman, S. Tsung-Ping, S.W. Tam, D.P. Taylor, Trends Pharmacol. Sci. 13, 85 (1992)
M. Hanner, F.F. Moebius, A. Flandorfer, H.G. Knaus, J. Striessnig, E. Kempner, H. Glossmann, Proc. Natl. Acad. Sci. USA 93, 8072 (1996)
W.D. Bowen, in Pharmacochemistry Library, edited by U. Gulini, M. Gianella, W. Quaglia, G. Marucci (Elsevier, 2000), pp. 211–218
B.J. Vilner, C.S. John, W.D. Bowen, Cancer Res. 55, 408 (1995)
E. Aydar, C.P. Palmer, M.B.A. Djamgoz, Cancer Res. 64, 5029 (2004)
J.E. Bermack, G. Debonnel, Br. J. Pharmacol. 134, 691 (2001)
C.S. John, W.D. Bowen, S.J. Fisher, B.B. Lim, B.C. Geyer, B.J. Vilner, R.L. Wahl, Nucl. Med. Biol. 26, 377 (1999)
B. Bourrie, E. Bribes, J.-M. Derocq, H. Vidal, P. Casellas, Curr. Opin. Investig. Drugs 5, 1158 (2004)
P. Brent, G. Pang, Eur. J. Pharmacol. 278, 151 (1995)
B.J. Vilner, B.R. deCosta, W.D. Bowen, J. Neurosci. Off. J. Soc. Neurosci. 15, 117 (1995)
P. Brent, G. Pang, G. Little, P. Dosen, D. Van Helden, Biochem. Biophys. Res. Commun. 219, 219 (1996)
T. Moody, J. Leyton, C. John, Life Sci. 66, 1979 (2000)
B.A. Spruce, L.A. Campbell, N. McTavish, M.A. Cooper, M.V.L. Appleyard, M. O’Neill, J. Howie, J. Samson, S. Watt, K. Murray, D. McLean, N.R. Leslie, S.T. Safrany, M.J. Ferguson, J.A. Peters, A.R. Prescott, G. Box, A. Hayes, B. Nutley, F. Raynaud, C.P. Downes, J.J. Lambert, A.M. Thompson, S. Eccles, Cancer Res. 64, 4875 (2004)
K.W. Crawford, A. Coop, W.D. Bowen, Eur. J. Pharmacol. 443, 207 (2002)
S. Elmore, Toxicol. Pathol. 35, 495 (2007)
M. Aboul-Enein, A. El-Azzouny, Y. Maklad, F. Ragab, M. Abdel-Maksoud, Egyptian. Pharm. J. 13, 1 (2014)
D. Mussoi, G. Boswell, N. Mehta, F. Soroko, C. Burchall, Eur. J. Med. Chem. 31, 331 (1996)
A. Kumar, B. Narasimhan, D. Kumar, Bioorg. Med. Chem. 15, 4113 (2007)
B. Narayana, K.K. VijayaRaj, B.V. Ashalatha, N.S. Kumari, B.K. Sarojini, Eur. J. Med. Chem. 39, 867 (2004)
G. Caliendo, V. Santagada, E. Perissutti, B. Severino, F. Fiorino, T.D. Warner, J.L. Wallace, D.R. Ifa, E. Antunes, G. Cirino, G. de Nucci, Eur. J. Med. Chem. 36, 517 (2001)
N. Charaya, D. Pandita, A.S. Grewal, V. Lather, Comput. Biol. Chem. 73, 221 (2018)
N.A. Gujarati, L. Zeng, P. Gupta, Z.-S. Chen, V.L. Korlipara, Bioorg. Med. Chem. Lett. 27, 4698 (2017)
M. Schlitzer, I. Sattler, A. Friese, I. Zündorf, T. Dingermann, Anticancer Res. 20, 1723 (2000)
J. Jiao, H. Fang, X. Wang, P. Guan, Y. Yuan, W. Xu, Eur. J. Med. Chem. 44, 4470 (2009)
A. Lu, H. Luo, M. Shi, G. Wu, Y. Yuan, J. Liu, F. Tang, Bioorg. Med. Chem. Lett. 21, 4924 (2011)
S. Nara, A. Garlapati, Ars Pharmaceutica (Internet) 59, 121 (2018)
M. Megahed, W. Fathalla, A.A. Alsheikh, J. Heterocycl. Chem. 55, 2799 (2018)
G.W. Anderson, J.E. Zimmerman, F.M. Callahan, J. Am. Chem. Soc. 86, 1839 (1964)
A.M. Alafeefy, A.A. Kadi, O.A. Al-Deeb, K.E.H. El-Tahir, N.A. Al-jaber, Eur. J. Med. Chem. 45, 4947 (2010)
A.S. El-Azab, M.A. Al-Omar, A.A.-M. Abdel-Aziz, N.I. Abdel-Aziz, M.A.-A. El-Sayed, A.M. Aleisa, M.M. Sayed-Ahmed, S.G. Abdel-Hamide, Eur. J. Med. Chem. 45, 4188 (2010)
M.R. Yadav, S.T. Shirude, A. Parmar, R. Balaraman, R. Giridhar, Chem. Heterocycl. Compd. 42, 1038 (2006)
V. Mittapelli, Der Pharma Chemica 6, 272 (2014)
S.M. El Rayes, I.A.I. Ali, W. Fathalla, Arkivoc 2008, 86 (2008)
E.F. Ismail, I.A.I. Ali, W. Fathalla, A.A. Alsheikh, E.S.E. Tamneya, Arkivoc 2017, 104 (2017)
C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Adv. Drug Deliv. Rev. 46, 3 (2001)
C.A. Lipinski, Drug Discovery Today: Technologies 1, 337 (2004)
P.D. Leeson, B. Springthorpe, Nat. Rev. Drug Discov. 6, 881 (2007)
D.E. Clark, S.D. Pickett, Drug Discovery Today 5, 49 (2000)
A.K. Ghose, T. Herbertz, R.L. Hudkins, B.D. Dorsey, J.P. Mallamo, A.C.S. Chem, Neuroscience 3, 50 (2012)
D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple, J. Med. Chem. 45, 2615 (2002)
M.S. Nafie, M.A. Tantawy, G.A. Elmgeed, Steroids 152, 108485 (2019)
H.R. Schmidt, S. Zheng, E. Gurpinar, A. Koehl, A. Manglik, A.C. Kruse, Nature 532, 527 (2016)
A.I. Khodair, M.A. Alsafi, M.S. Nafie, Carbohyd. Res. 486, 107832 (2019)
M.G. Salem, Y.M.A. Aziz, M. Elewa, H.A. Elshihawy, M.M. Said, Bioorg. Med. Chem. 27, 3383 (2019)
A. Daina, O. Michielin, V. Zoete, Sci. Rep. 7, 42717 (2017)
T. Mosmann, J. Immunol. Methods 65, 55 (1983)
R. Ian, Freshney, Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications (Wiley-Blackwell, Hoboken, 2010)
Funding
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
EY synthesized the entire series of new amine, amino acid and dipeptide-coupled benzamide derivatives under main supervision of WF and MAEM, who designed the idea and supervised the synthesis and characterization part. MSN initiated the idea and design of the biology part by carrying out in silico molecular docking and bioinformatics, cytotoxic screening. All authors contributed to data analysis and manuscript writing in their corresponding parts. MSN carried out the linguistic revision for the whole manuscript and validated it in the final submitted form, and additionally, he followed up the publication process from submission through the review to acceptance.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
13738_2020_1947_MOESM1_ESM.rar
The bioinformatics data of the investigated compounds together with spectroscopic characterization charts, some biological activity data are provided as supporting information online (RAR 11530 kb)
Rights and permissions
About this article
Cite this article
Youssef, E., El-Moneim, M.A., Fathalla, W. et al. Design, synthesis and antiproliferative activity of new amine, amino acid and dipeptide-coupled benzamides as potential sigma-1 receptor. J IRAN CHEM SOC 17, 2515–2532 (2020). https://doi.org/10.1007/s13738-020-01947-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13738-020-01947-6